semaglutide gray market Many people start and stop GLP-1s. Here's why that may be a bad idea : NPR Study Finds GLP-1s Are Effectively

A recent report from health insurance data non-profit organisation FAIR Health suggested that more than 2% of adult Americans are using GLP-1 therapies for obesity or those who are overweight, approximately 5 million people

Duloxetine is a medication that belongs to the class of drugs known as selective serotonin and norepinephrine reuptake inhibitors (SSNRIs)

A1C reductions of 2.02% in diabetic participants, triglyceride reductions of 28%, and blood pressure improvements of 6.8mmHg systolic all maintained through the study period

For people with type 2 diabetes and early-stage kidney problems, this treatment could offer a better way to protect kidney function and improve overall health

The key to future success will be adapting product selections and marketing to line up with the new health-focused mindset of this growing group of shoppers.

Ahmann A, Chow F, Vivian F, et al